| Literature DB >> 29081609 |
Paramasivan Manivannan1, Gangatharan Muralitharan1, Nainangu Prasanna Balaji1.
Abstract
Marine Lyngbya has been proven as a potent anticancer agent by disrupting microfilament network. Lyngbya and its associated cyanobacterial compounds have been stressed for futuristic advancements in cancer research and have foreseen explicit advancements in the recent era. Moreover, compounds like lyngbyabellins, lyngbyastatins and other derived toxins are significantly studied. Therefore it is of interest to study the efficacies of Lyngbya fatty acid derivatives. Cytotoxicity and DNA laddering studies proves the efficiency and safety of marine Lyngbya. Caspase - 3 along with MMP2 and MMP9 affirms the anti-inflammatory properties. Molecular docking shows that Octadecanoic acid has strong binding affinity to MMP-2. The role of octadecanoic acid as a proapoptotic factor in emancipation of inflammation apart from inducing apoptosis is of interest to study in future.Entities:
Keywords: Interaction assessment; Lyngbya; MMP-2; anti-inflammatory activity; octadecanoic acid; proapoptotic factor
Year: 2017 PMID: 29081609 PMCID: PMC5651223 DOI: 10.6026/97320630013301
Source DB: PubMed Journal: Bioinformation ISSN: 0973-2063
Notable anticancer compounds from Lyngbya
| Compounds | Source | Mode of action |
| Curacin A | Lyngbya majuscula | Inhibition of microtubule assembly |
| Dolastatin 15, Cematodin (LU-103793), ILX-651 (Synthadotin) | Lyngbya sp. | Breast cancer abatement |
| Apratoxin A | Lyngbya sp. | Efficient in arresting early stage adenocarcinoma |
| Somocystinamide | Lyngbya majuscula/ | Cyto toxicity against mouse |
| A | Schizothrix sp. Assemblage | neuro-2a neuroblastoma |
| Lyngbic acid and malyngamide C | L. majuscula | Cytotoxic against HT29 colon cancer |
| Apratoxin D | L. majuscula and L. sordida | Cancer cell toxicity |
| Apratoxin E, | L. bouillonii | Cytotoxicity |
| Caylobolide A | L. majuscula | In vitro cytotoxicity against human colon tumor cells |
| Lyngbyaloside | L. bouillonii | |
| Lyngbyabellin J, laingolide B, lyngbyapeptin D, lyngbyabellins A and B, lyngbyapeptin A, and lyngbyaloside | L. bouillonii | Cytotoxicity |
| Curacins B and C | L. bouillonii | Cytotoxicity against murine L-1210 leukemia and human CA46 Burkitt lymphoma cell lines |
| Itralamide B | L. majuscula | Cytotoxicity against human embryonic kidney (HEK293) |
| Hantupeptin A | L. majuscula | Cytotoxicity to MOLT-4 leukemia cells and MCF-7 breast cancer cells |
| Lyngbyabellin A | L. majuscula | Disruption of cellular microfilament network |
| Lagunamides A and B | L. majuscula | Cytotoxic activity against P388 murine leukemia cell lines |
Figure 1Depicts the sampling site mandapam in the Gulf of Mannar region with accurate eight latitude and longitude.
Figure 2The MTT assay profiles indicating high cytotoxicity of aqueous extracts of 5 Lyngbya sp against HepG2 and MCF cell lines.
Figure 3Demonstrates the anti inflammatory profiles of intracellular and extracellular 4 extracts of Lyngbya sp with high fold ratio for extracellular extracts showing its 5 therapeutic profile.
Figure 4Contrarily shows that intracellular extracts possess high DNA fragmentation 4 activities.
Figure 5Indicates the hydrogen bond donor ARG133 with varied hydrogen acceptors.